U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07867171) titled 'A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on Velzatinib' on Oct. 01.

Brief Summary: This study evaluates the effect of moderate and severe renal impairment on the pharmacokinetics (PK) of velzatinib compared with normal renal function.

Study Start Date: Oct. 23

Study Type: INTERVENTIONAL

Condition: Healthy Participants Gastrointestinal Neoplasms

Intervention: DRUG: Velzatinib

Velzatinib will be administered.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: GlaxoSmithKline

Disclaimer: Curated by HT Syndication....